NSD1 stimulated survival and migration of gastric cancer cells through WNT10B

Background and objective: To assess the expression of Nuclear receptor binding SET domain protein 1 (NSD1) in human gastric cancer tissues and cells and investigate its possible role in gastric cancer.

Methods: TCGA database was used to assess the expression levels of NSD1 in human gastric cancer tissues. Immunoblot assays were performed to detect NSD1 expression levels in gastric cancer cell lines. MTT and colony formation assays were conduced to detect its role in the survival of gastric cancer cells. Wound closure and transwell were performed to investigate the effects of NSD1 on the motility of gastric cancer cells. Immunoblot assays were also conducted to confirm its effects on WNT10B/β-catenin pathway.

Results: We found the high expression levels of NSD1 in human gastric cancer tissues and cell lines. NSD1 depletion suppressed the survival and motility of gastric cancer cells. Additionally, we revealed NSD1 activated the WNT10B/β-catenin pathway, therefore promoted gastric cancer progression.

Conclusion: We revealed the high NSD1 expression in gastric cancer tissues and cells, and thought NSD1 could serve as a promising gastric cancer target.

Nuclear receptor binding SET domain protein 1 (NSD1); Gastric cancer; Survival; Motility; WNT10B/β-catenin

[1] Lin L, Liu Y, Pan C, Zhang J, Zhao Y, Shao R, et al. Gastric cancer cells escape metabolic stress via the DLC3/MACC1 axis. Theranostics. 2019; 9: 2100–2114.

[2] Liang Y, Liu Y, Zhang Q, Zhang H, Du J. Tumor-derived extracellular vesicles containing microRNA-1290 promote immune escape of cancer cells through the Grhl2/ZEB1/PD-L1 axis in gastric cancer. Translational Research. 2021; 231: 102–112.

[3] Noh M, Yoon Y, Kim G, Kim H, Lee E, Kim Y, et al. Practical prediction model of the clinical response to programmed death-ligand 1 inhibitors in advanced gastric cancer. Experimental & Molecular Medicine. 2021; 53: 223–234.

[4] Bennett RL, Swaroop A, Troche C, Licht JD. The role of nuclear receptor-binding set domain family histone lysine methyltransferases in cancer. Cold Spring Harbor Perspectives in Medicine. 2017; 7: a026708.

[5] Lucio-Eterovic AK, Singh MM, Gardner JE, Veerappan CS, Rice JC, Carpenter PB. Role for the nuclear receptor-binding SET domain pro-tein 1 (NSD1) methyltransferase in coordinating lysine 36 methylation at histone 3 with RNA polymerase II function. Proceedings of the National Academy of Sciences of the United States of America. 2010; 107: 16952–16957.

[6] di Luccio E. Inhibition of nuclear receptor binding set domain 2/multiple myeloma set domain by LEM-06 implication for epigenetic cancer therapies. Journal of Cancer Prevention. 2015; 20: 113–120.

[7] Pan C, Izreig S, Yarbrough WG, Issaeva N. NSD1 mutations by HPV status in head and neck cancer: differences in survival and response to DNA-damaging agents. Cancers of the Head & Neck. 2019; 4: 3.

[8] Ettel M, Zhao L, Schechter S, Shi J. Expression and prognostic value of NSD1 and SETD2 in pancreatic ductal adenocarcinoma and its precursor lesions. Pathology. 2019; 51: 392–398.

[9] Wu X, Bie Q, Zhang B, Yan Z, Han Z. Wnt10B is critical for the progression of gastric cancer. Oncology Letters. 2017; 13: 4231–4237.

[10] Aziz A, Irfanullah, Khan S, Zimri FK, Muhammad N, Rashid S, et al. Novel homozygous mutations in the WNT10B gene underlying auto-somal recessive split hand/foot malformation in three consanguineous families. Gene. 2014; 534: 265–271.

[11] Zhen T, Dai S, Li H, Yang Y, Kang L, Shi H, et al. MACC1 promotes carcinogenesis of colorectal cancer via beta-catenin signaling pathway. Oncotarget. 2014; 5: 3756–3769.

[12] Obatake M, Sato K, Yagi S, Ohtani H, Kito K. IgG4-related gastric disease with plasma cell-rich obliterative arteritis accompanied by early-stage gastric cancer: a case report. Surgical Case Reports. 2021; 7: 40.

[13] Pan T, Chen W, Yuan X, Shen J, Qin C, Wang L. MiR-944 inhibits metastasis of gastric cancer by preventing the epithelial-mesenchymal transition via MACC1/Met/AKT signaling. FEBS Open Bio. 2017; 7: 905–914.

[14] Tong G, Cheng B, Li J, Wu X, Nong Q, He L, et al. MACC1 regulates PDL1 expression and tumor immunity through the c-Met/AKT/mTOR pathway in gastric cancer cells. Cancer Medicine. 2019; 8: 7044–7054.

[15] Wang K, Wang H, Lv Y, Liu H, Liu J, Zhang Y. Camrelizumab combined with lenvatinib in the treatment of gastric cancer with liver metastasis: a case report. Annals of Palliative Medicine. 2021; 10: 803–809.

[16] Su X, Zhang J, Mouawad R, Compérat E, Rouprêt M, Allanic F, et al. NSD1 inactivation and SETD2 mutation drive a convergence toward loss of function of H3K36 writers in clear cell renal cell carcinomas. Cancer Research. 2017; 77: 4835–4845.

[17] Zhang S, Zhang F, Chen Q, Wan C, Xiong J, Xu J. CRISPR/Cas9-mediated knockout of NSD1 suppresses the hepatocellular carcinoma development via the NSD1/H3/Wnt10b signaling pathway. Journal of Experimental & Clinical Cancer Research. 2019; 38: 467.

[18] Brennan K, Shin JH, Tay JK, Prunello M, Gentles AJ, Sunwoo JB, et al. NSD1 inactivation defines an immune cold, DNA hypomethylated subtype in squamous cell carcinoma. Scientific Reports. 2017; 7: 17064.

[19] Peri S, Izumchenko E, Schubert AD, Slifker MJ, Ruth K, Serebriiskii IG, et al. NSD1- and NSD2-damaging mutations define a subset of laryngeal tumors with favorable prognosis. Nature Communications. 2017; 8: 1772.

[20] Wang GG, Cai L, Pasillas MP, Kamps MP. NUP98-NSD1 links H3K36 methylation to Hox-A gene activation and leukaemogenesis. Nature Cell Biology. 2007; 9: 804–812.

[21] Nagai T. Sotos syndrome and haploinsufficiency of NSD1: clinical features of intragenic mutations and submicroscopic deletions. Journal of Medical Genetics. 2003; 40: 285–289.

[22] Streubel G, Watson A, Jammula SG, Scelfo A, Fitzpatrick DJ, Oliviero G, et al. The H3K36me2 methyltransferase Nsd1 demarcates PRC2-Mediated H3K27me2 and H3K27me3 domains in embryonic stem cells. Molecular Cell. 2018; 70: 371–379.e5.

[23] Peng L, Liu Z, Xiao J, Tu Y, Wan Z, Xiong H, et al. MicroRNA-148a suppresses epithelial-mesenchymal transition and invasion of pancreatic cancer cells by targeting Wnt10b and inhibiting the Wnt/β-catenin signaling pathway. Oncology Reports. 2017; 38: 301–308.

[24] Chen H, Wang Y, Xue F. Expression and the clinical significance of Wnt10a and Wnt10b in endometrial cancer are associated with the Wnt/β-catenin pathway. Oncology Reports. 2013; 29: 507–514.

[25] Zhang S, Zhang F, Chen Q, Wan C, Xiong J, Xu J. CRISPR/Cas9-mediated knockout of NSD1 suppresses the hepatocellular carcinoma development via the NSD1/H3/Wnt10b signaling pathway. Journal of Experimental & Clinical Cancer Research. 2019; 38: 467.